Niclosamide Overcomes Acquired Resistance to Erlotinib Through Suppression of STAT3 in Non-Small Cell Lung Cancer

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-13-0095
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Targeting Heat Shock Protein 90 With CUDC-305 Overcomes Erlotinib Resistance in Non-Small Cell Lung Cancer

Molecular Cancer Therapeutics
Cancer ResearchOncology
2009English

Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non-Small Cell Lung Cancer

Cancer Research
Cancer ResearchOncology
2015English

Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2017English

Screening Circular RNAs Related to Acquired Gefitinib Resistance in Non-Small Cell Lung Cancer Cell Lines

Journal of Cancer
Oncology
2020English

Effects of AKT Inhibition on HGF-mediated Erlotinib Resistance in Non-Small Cell Lung Cancer Cell Lines

Journal of Cancer Research and Clinical Oncology
MedicineCancer ResearchOncology
2014English

Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells Through Downregulation of Akt

Journal of Cancer
Oncology
2011English

P2.13-37 Chloroquine Overcomes Acquired Resistance to Icotinib in Vitro and in Vivo Through STAT3/STMN1 Pathway

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Erlotinib Resistance With EGFR L858r/Y891d Double Mutation in a Patient With Non–Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Non-Small Cell Lung Cancer-Small Cell Lung Cancer Transformation as Mechanism of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy